Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

about

Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

Item

http://www.wikidata.org/entity/Q57815283

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@en

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@nl

type

Item

label

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@en

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@nl

prefLabel

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@en

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@nl

P1476

Updated Canadian Expert Consen ...... nant Polycystic Kidney Disease

@en

P2093

Ahsan Alam

http://www.w3.org/2001/XMLSchema#string

Daniel G Bichet

http://www.w3.org/2001/XMLSchema#string

Louis-Philippe Girard

http://www.w3.org/2001/XMLSchema#string

Micheli Bevilacqua

http://www.w3.org/2001/XMLSchema#string

Paul Komenda

http://www.w3.org/2001/XMLSchema#string

Paul Tam

http://www.w3.org/2001/XMLSchema#string

Philip McFarlane

http://www.w3.org/2001/XMLSchema#string

Rolf Loertscher

http://www.w3.org/2001/XMLSchema#string

Sanjaya Pandeya

http://www.w3.org/2001/XMLSchema#string

Steven Soroka

http://www.w3.org/2001/XMLSchema#string

P2860

Autosomal dominant polycystic kidney disease: the last 3 years

Evidence-based clinical practice guidelines for polycystic kidney disease 2014

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Current management of autosomal dominant polycystic kidney disease

PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group.

Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group.

Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.

Renal function and healthcare costs in patients with polycystic kidney disease.

P304

2054358118801589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2054358118801589

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30345064

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

autosomal dominant polycystic kidney disease

P932

6187423

http://www.w3.org/2001/XMLSchema#string